CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
Authors:
- Richard R LoveRLRichard R Love
- David FlockhartDFDavid Flockhart
- Todd SkaarTSTodd Skaar
- Evan T OgburnEOEvan T Ogburn
- Anuradha RamamoorthyARAnuradha Ramamoorthy
- Gemma B UyGUGemma B Uy
- Adriano V LaudicoALAdriano V Laudico
- Nguyen Van DinhNDNguyen Van Dinh
- Le Hong QuangLQLe Hong Quang
- Ta Van ToTTTa Van To
- Gregory S YoungGYGregory S Young
Open Access
- 15 February 2013
- journal article
- research article
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 52
Abstract
While tamoxifen activity is mainly due to endoxifen and the concentration of this active metabolite is, in part, controlled by CYP2D6 metabolic status, clinical correlative studies have produced mixed results. In an exploratory study, we determined the CYP2D6 metabolic status and plasma concentrations of endoxifen among 224 Filipino and Vietnamese women participating in a clinical trial of adjuvant hormonal therapy for operable breast cancer. We further conducted a nested-case–control study among 48 women (half with recurrent disease, half without) investigating the relationship of endoxifen concentrations and recurrence of disease. We found a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6 genotypes. High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002. The trend also showed that in 8 out of 9 pairs with low endoxifen concentrations, the recurrent case had lower endoxifen levels than the matched control. This exploratory analysis suggests that there is an optimal range for endoxifen concentrations to achieve favorable effects as adjuvant therapy. In particular, at higher concentrations (>70 ng.ml), endoxifen may promote recurrence.Keywords
This publication has 14 references indexed in Scilit:
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter StudyJournal of Clinical Oncology, 2011
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer PatientsJournal of Clinical Oncology, 2010
- Orally administered Endoxifen is a new therapeutic agent for breast cancerBreast Cancer Research and Treatment, 2010
- Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast CancerClinical Cancer Research, 2008
- A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients?JNCI: Journal of the National Cancer Institute, 2008
- Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatmentClinical Pharmacology & Therapeutics, 2006
- CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2005
- Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6The Journal of Pharmacology and Experimental Therapeutics, 2004
- CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendantsPharmacogenomics, 2002
- Software for optimal matching in observational studies.1996